Dishman Carbogen Amcis Ltd, a leading name in pharmaceutical manufacturing and development, has successfully completed the US Food and Drug Administration (US FDA) inspection of its Naroda facility in Ahmedabad, India. The inspection, carried out between June 9 and June 13, 2025, was completed ahead of schedule on June 12, 2025, without any observations or compliance concerns. Today, the company announced receipt of the Establishment Inspection Report (EIR) from the US FDA, marking a formal closure of the inspection process—cementing its regulatory compliance and operational excellence.
Key Highlights of the US FDA Inspection and EIR Receipt
-
The US FDA inspected the Naroda facility over five days (June 9–13, 2025), focusing on compliance with current good manufacturing practices (cGMP), regulatory standards, and quality systems.
-
The inspection was successfully completed on June 12, 2025, with no observations or issuance of a Form 483, indicating a flawless audit.
-
Receipt of the Establishment Inspection Report (EIR) confirms the US FDA’s satisfaction with the facility’s operations, formally closing the inspection.
-
Prior notification of the inspection completion was made to the stock exchanges on June 13, 2025, demonstrating transparency and prompt communication.
-
Dishman Carbogen Amcis’ other critical manufacturing facilities—in Bavla (India), Switzerland, and the Netherlands—remain fully US FDA approved, underscoring the company’s robust global compliance profile.
Inspection Details and Significance
The 2025 US FDA inspection targeted the Naroda facility’s manufacturing processes and regulatory adherence, pivotal for ensuring quality APIs (Active Pharmaceutical Ingredients) that meet stringent US market standards. The zero-observation outcome signifies that all aspects of the quality systems, process controls, documentation, and manufacturing standards conform impeccably to US FDA norms.
The successful closure of the inspection not only validates Dishman Carbogen Amcis’ unwavering focus on quality and compliance but also enhances the company’s credibility in the regulated pharmaceutical markets. Maintaining uninterrupted US FDA approval is crucial for the company’s ability to supply to the United States—a demanding and lucrative market—thus boosting its competitive edge and growth potential.
Company’s Ongoing Commitment and Global Presence
Dishman Carbogen Amcis operates multiple facilities worldwide, with significant manufacturing hubs in India (Naroda and Bavla), Switzerland, and the Netherlands. The US FDA’s continued approval of these sites reflects the company’s persistent dedication to maintaining premier quality standards across its operations.
The leadership at Dishman Carbogen Amcis expressed pride in this achievement, emphasizing that the EIR receipt from the US FDA is a testament to their strategic investments in quality systems and regulatory readiness. The facility’s compliance success supports the company’s mission to provide high-standard pharmaceutical products and helps foster stronger partnerships with global clients reliant on regulatory-certified suppliers.
Industry and Market Impact
For investors and stakeholders, this update confirms Dishman Carbogen Amcis’ strong regulatory standing, which is integral to its operational sustainability and reputation in the contract research and manufacturing services (CRAMS) segment. The announcement comes amid a period when the company reported a significant turnaround in financial performance, including a consolidated net profit rise to Rs 43.09 crore in Q4 March 2025, up from a net loss the previous year. Revenue from operations also rose 9.41% year-on-year, reflecting operational resilience and market demand.
This FDA approval reinforces the company’s growth story by ensuring its drug substances remain eligible for export to the US and other regulated markets, which depend heavily on FDA-compliant manufacturers. It also allays any concerns on regulatory risks that could adversely affect supply continuity or market confidence.
Summary and Outlook
Dishman Carbogen Amcis’ Naroda facility successfully passing the US FDA inspection and receiving the Establishment Inspection Report (EIR) confirms the company’s sustained commitment to excellence in pharmaceutical manufacturing. With all its major manufacturing units continuing to meet US FDA standards, the company is well-positioned to capitalize on growing global demand for high-quality APIs and development services.
This milestone strengthens Dishman Carbogen Amcis’ global market positioning, boosts investor confidence, and points to continued operational stability and compliance adherence in the foreseeable future.
Source: Official company disclosures to BSE and NSE, Reuters, Market Screener, Business Standard, IMDCAL News
